OIS@ASCRS

Mike Judy, CEO, Refocus Group, a company dedicated to non-invasive surgical solutions for presbyopia, presented early data on the its ongoing clinical trial. The firm…

Jim McCollum, Co-founder & Board member, introduced LiquidVision, an eye drop regimen that might correct presbyopia. The drops would be administered daily, or as needed,…

Board member Gerd Auffarth, MD, shared his unique perspective on Presbia’s Flexivue Microlens designed to eliminate the need for reading glasses.

Barry Cheskin, Co-founder, President, & CEO, delivered early results on the release of FluidVision 2020 into the clinic. The company reports 24 successful surgeries to…

Gary Wörtz, MD, chief medical officer of Omega Ophthalmics, allowed OIS attendees to see the first public implantation of his company’s Omega Gemini Refractive Capsule.…

Jonathan Talamo, MD, chief medical officer at Ocular Therapeutix updated OIS@ASCRS attendees on the clinical progress of Dextenza, which is the subject of an NDA…

John Hendrick, president and CEO of Mynosys Cellular Devices, reported strong progress for Zepto, a disposable capsulotomy device. The company completed US clinical trials and…

Bob Butchofsky, CEO of Mati Therapeutics, updated OIS@ASCRS on the company’s punctal plug delivery system, introducing 12-week data from a Phase II multicenter clinical trial…

Chris Geddes, MD, chief biomedical/plasmonics consultant at LacriScience, previously introduced his company’s LacriPen as a method of measuring tear osmality. In this presentation, Dr. Geddes…

Dave Van Meter, president and CEO of Ivantis, updated OIS@ASCRS attendees on the Hydrus Microstent. Ivantis, like Glaukos, is focused on using the Schlemm’s canal…

Russ Trenary, president and CEO of InnFocus, updated OIS@ASCRS on the progress of MicroShunt, which the company says could be the first and only surgical…

Stephen From, CEO of EyeGate Pharma, updated OIS@ASCRS on its acquisition of Jade Therapeutics’ Hyaluronic Acid program. The company paired the HA to create the…